Advertisement

Topics

Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment

2014-11-24 06:22:40 | BioPortfolio

Published on BioPortfolio: 2014-11-24T06:22:40-0500

Clinical Trials [2054 Associated Clinical Trials listed on BioPortfolio]

Clinical Research in Hairy Cell Leukemia:Surveillance and Documentation of Clinical Outcomes

The overall objective is to develop a clinical data registry that can be used to facilitate research with the ultimate goal of reducing the morbidity and/or mortality and improving the qua...

Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia

This phase II trial studies how well ibrutinib works in treating patients with relapsed hairy cell leukemia. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes n...

Daily or Weekly Cladribine in Treating Patients With Hairy Cell Leukemia

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if giving cladribine once a day is more effectiv...

Rituximab in Hairy Cell Leukemia: a Multicenter Retrospective Study

Hairy-cell leukemia is a rare and indolent lymphoid disorder, representing 2% of all cases of lymphoid leukemias. Treatment of hairy-cell leukemia relies mainly on the purine analogs, clad...

BL22 Immunotoxin in Treating Patients Previously Treated With Cladribine for Hairy Cell Leukemia

RATIONALE: The BL22 immunotoxin can locate tumor cells and kill them without harming normal cells. This may be an effective treatment for hairy cell leukemia that has not responded to trea...

PubMed Articles [16248 Associated PubMed Articles listed on BioPortfolio]

Novel therapeutics in the treatment of hairy cell leukemia variant.

New Hairy Cell Leukemia Therapy.

Antibiotic exposure is associated with cutaneous adverse events in hairy cell leukemia patients treated with purine analogs.

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia.

This is a pivotal, multicenter, open-label study of moxetumomab pasudotox, a recombinant CD22-targeting immunotoxin, in hairy cell leukemia (HCL), a rare B cell malignancy with high CD22 expression. T...

Donor cell-derived acute promyelocytic leukemia after allogeneic hematopoietic stem cell transplantation.

Allogeneic hematopoietic stem cell transplantation (HSCT) is the one of treatment known to cure acute myeloid leukemia (AML). Relapse of AML remains the major cause of treatment failure in patients af...

Medical and Biotech [MESH] Definitions

A neoplastic disease of the lymphoreticular cells which is considered to be a rare type of chronic leukemia; it is characterized by an insidious onset, splenomegaly, anemia, granulocytopenia, thrombocytopenia, little or no lymphadenopathy, and the presence of "hairy" or "flagellated" cells in the blood and bone marrow.

An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia.

A potent inhibitor of ADENOSINE DEAMINASE. The drug induces APOPTOSIS of LYMPHOCYTES, and is used in the treatment of many lymphoproliferative malignancies, particularly HAIRY CELL LEUKEMIA. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.

T Lymphocytes with limited diversity of receptors (e.g., ALPHA E INTEGRINS) in the epidermis of the skin and the mucosal linings. They recognize common microbes via T-CELL RECEPTORS and PATHOGEN-ASSOCIATED MOLECULAR PATTERN MOLECULES and function as effector cells for INNATE IMMUNITY. Activation of intraepithelial lymphocytes is a marker for various gastrointestinal diseases (e.g., CELIAC DISEASE; HAIRY CELL LEUKEMIA; and ENTEROPATHY-ASSOCIATED T-CELL LYMPHOMA).

A lymphoid leukemia characterized by a profound LYMPHOCYTOSIS with or without LYMPHADENOPATHY, hepatosplenomegaly, frequently rapid progression, and short survival. It was formerly called T-cell chronic lymphocytic leukemia.

More From BioPortfolio on "Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial